I'm thinking the same. The K-OC trial was planned as a P1b/P2 trial in combination with doxuribicin. Shortly after Dr. B joined CTIX, it was changed to a P2a POC trial. Here's a hint:
“Our near-term focus is now on preparing for a Phase 2a trial of Kevetrin in treating late-stage ovarian cancer, which we anticipate will start in the fourth quarter this year,” said Cellceutix President and Chief Medical Officer Dr. Arthur P. Bertolino. “This will be a small trial that will move quickly with the end goal to provide the critical data necessary to forge a partnership with a large pharmaceutical company interested in co-developing Kevetrin as it makes progress toward possibly becoming the first p53-activating drug approved by the FDA.”
http://www.cellceutix.com/press-release/2016/...pline-data
Another hint:
"As far as our cancer program with Kevetrin, we believe that the position for partnering will be once we have data from our small Phase 2a study that is in preparation aimed to firmly establish the p53 modulation in the tumor as the mechanism of action and as we transition into oral dosing formulation."
http://investorshangout.com/post/view?id=4172037
Sounds like at least one BP has requested the p53 data.
“Our near-term focus is now on preparing for a Phase 2a trial of Kevetrin in treating late-stage ovarian cancer, which we anticipate will start in the fourth quarter this year,” said Cellceutix President and Chief Medical Officer Dr. Arthur P. Bertolino. “This will be a small trial that will move quickly with the end goal to provide the critical data necessary to forge a partnership with a large pharmaceutical company interested in co-developing Kevetrin as it makes progress toward possibly becoming the first p53-activating drug approved by the FDA.”
http://www.cellceutix.com/press-release/2016/...pline-data
Another hint:
"As far as our cancer program with Kevetrin, we believe that the position for partnering will be once we have data from our small Phase 2a study that is in preparation aimed to firmly establish the p53 modulation in the tumor as the mechanism of action and as we transition into oral dosing formulation."
http://investorshangout.com/post/view?id=4172037
Sounds like at least one BP has requested the p53 data.
Quote:Sox I can't believe they have just decided to do this on their own without believing or knowing some one has real interest.
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
